➡ Upstream Target
Alzheimer's disease
✗ KILL CRITERIA
- APOE4→APOE3 conversion shows no amyloid reduction in Phase 3 trial
- APOE isoform switching fails to improve cognitive endpoints at 18 months
- Lipid代谢 correction fails to modify disease progression in APOE4 carriers